Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07210086) titled 'Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)' on Sept. 29.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: City of Hope Medical Center
Condition:
Prostate Cancer
Intervention:
Drug: ADT
Drug: ARSI
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 11, 2025
Target Sample Size: 50
Countries of Recruitment:
United States
To know more, ...